Novo’s weight-loss drug Wegovy gets CDSCO approval for fatty liver disease
2 sources·Updated July 17, 2026
Covered by 2 sources
- Business Today IN·6d agoNovo Nordisk's obesity drug Wegovy wins government approval for fatty liver disease treatment
Novo Nordisk said about two in three people in India have fatty liver disease, which offers immense potential for the drugmaker due to the vast patient population.
Read at Business Today IN → - Hindustan Times India·6d agoNovo’s weight-loss drug Wegovy gets CDSCO approval for fatty liver disease
The CDSCO has approved a new indication for Wegovy (semaglutide injection 2.4 mg) for treatment of noncirrhotic metabolic dysfunction associated steatohepatitis (MASH) in adults
Read at Hindustan Times India →